ArticleFrontiers in medicine2026
Case Report: Successful treatment of pediatric patients with acute generalized pustular psoriasis with secukinumab.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute generalized pustular psoriasis (GPP) is a rare, distinct subtype of psoriasis characterized clinically by sterile pustules arising on an erythematous base. Pediatric GPP is associated with severe manifestations, high healthcare expenditures, and a great risk of mortality, severely affecting the quality of life of both children and their families. Secukinumab, a fully human monoclonal antibody that selectively targets IL-17A-a pivotal cytokine in psoriasis pathogenesis that promotes keratinocyte proliferation and inflammatory responses-has been approved for the treatment of moderate-to-severe plaque psoriasis in children aged 6-18 years. Here, we describe three pediatric patients with GPP who were successfully treated with secukinumab. To date, no secukinumab-related adverse effects have been observed among the three pediatric patients throughout their respective follow-up periods. Secukinumab may be an effective option for the treatment of GPP in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.